Impact of COVID‐19 lockdown on routine oncology versus emergency care at a high volume cancer centre. (4th June 2021)

• Record Type: Journal Article
• Authors: Minichsdorfer, Christoph; Jeryczynski, Georg; Krall, Christoph; Achhorner, Alina Magdalena; Caraan, Ariane; Pasalic, Sabina; Reininger, Katharina; Wagner, Christina; Bartsch, Rupert; Preusser, Matthias; Laggner, Anton; Raderer, Markus; Fuereder, Thorsten
• Is Part Of: European journal of clinical investigation. Volume 51:Number 8(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-04
• Subjects: COVID‐19 -- lockdown -- oncology -- oncologic basic care -- oncologic emergency; Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.13623
• Languages: English
• ISSNs: 0014-2972

Abstract

Abstract: Background: We investigated the influence of population‐wide COVID‐19 lockdown measures implemented on 16, March 2020 on routine and emergency care of cancer outpatients at a tertiary care cancer centre in Vienna, Austria. Methods: We compared the number/visits of cancer outpatients receiving oncological therapies at the oncologic day clinic (DC) and admissions at the emergency department (ED) of our institution in time periods before (pre‐lockdown period: 1 January – 15 March 2020) and after (post‐lockdown period: 16 March– 31 May 2020) lockdown implementation with the respective reference periods of 2018 and 2019. Additionally, we analysed Emergency Severity Index (ESI) score of unplanned cancer patient presentations to the ED in the same post‐lockdown time periods. Patient outcome was described as 3‐month mortality rate (3‐MM). Results: In total, 16 703 visits at the DC and 2664 patient visits for the respective time periods were recorded at the ED. No decrease in patient visits was observed at the DC after lockdown implementation ( P = .351), whereas a substantial decrease in patient visits at the ED was seen ( P < .001). This translates into a 26%‐31% reduction of cancer‐related patient visits per half month after the lockdown at the ED ( P < .001 vs. 2018 + 2019). There was no difference in the distribution of ESI scores at ED presentation ( P = .805), admission rates or 3‐MM in association with lockdown implementation ( P = .086). Conclusion: We demonstrate the feasibility of maintaining antineoplastic therapy administration during the COVID‐19 pandemic. However, our data underline the need for adapted management strategies for emergency presentations of cancer patients.